Heme Malignancy
SHOP PRODUCTS
Overview
The molecular analysis of heme malignancies now includes NGS as complementary technology to the traditional methods such as FISH and qPCR. NGS hematological disorder assays developed and deployed to profile patients for these malignancies provide a highly multiplexed analysis of genomic aberrations that underpin many of these diseases. Assay development, validation and clinical deployment will often require the use of clinical patient samples to aid these efforts. However, due to the vast diversity of genetic alterations in blood cancers, it can be a monumental and expensive task to source sufficient quantities of remnant patient specimens and cell lines bearing clinically relevant variants across these different diseases.
To both accelerate and lower the cost of validating NGS assays for these disorders, we have developed highly multiplexed, be-spoke biosynthetic RNA and DNA reference materials for NGS-based assays designed to analyze hematologic malignancies such as Myeloid Leukemia and Lymphoma.
Seraseq® Myeloid Products
Consists of the following products:
- Seraseq Myeloid Mutation DNA Mix, p/n 0710-0409
- Seraseq Myeloid Fusion RNA Mix, p/n 0710-0407
These products are compatible with a range of NGS Myeloid assays such as;
- AmpliSeq™ for Illumina Myeloid Panel
- Thermo Fisher Oncomine® Focus and Oncomine Myeloid Research Assay
- Archer® VariantPlex® and FusionPlex® Panels
- Illumina TruSight® Myeloid Sequencing Panel
Gene List - DNA Mix
| ABL1 |
CBL |
IDH1 |
NPM1 |
| ASXL1 |
CEBPA |
JAK2 |
SF3B1 |
| BRAF |
CSF3R |
MPL |
SRSF2 |
| CALR |
FLT3 |
MYD88 |
U2AF1 |
Gene List - RNA Fusions
| BCR-ABL1 |
FIP1L1-PDGFRA |
PML-RAR⍺ |
| ETV6-ABL1 (transcript 1) |
MYST3-CREBBP |
RUNX1-RUNX1T1 |
| ETV6-ABL1 (transcript 2) |
PCM1-JAK2 |
TCF3-PBX1 |
Features and attributes:
- Expert-designed constructs with clinically relevant variants
- Highly multiplexed - 23 DNA variants and 9 RNA fusion gene variants
- Broad variant types - SNVs, INDELs, and SVs
- Customizable and flexible content
- Manufactured under cGMP and ISO 13485
Seraseq® Lymphoma DNA Products
Consists of the following products:
- Seraseq Lymphoma DNA Mutation Mix; p/n: 0710-2203
- Seraseq FFPE Lymphoma DNA Reference Material; p/n: 0710-2202
Gene List - Lymphoma DNA Products
| BCL2 |
NOTCH1 |
NPM1-ALK |
BRAF |
NOTCH2 |
| HSP90AA1-BCL6 |
DNMT3A |
RHOA |
CCND1-CDC42BPB |
EZH2 |
| SF3B1 |
BIRC3-MALT1 |
IDH2 |
STAT3 |
MYC-IGH |
| MYD88 |
STAT5B |
TBL1XR1-TP63 |
CXCR4 |
TP53 |
Features and attributes:
- Designed and manufactured to support NGS assays for Lymphoma patient disease profiling
- Highly multiplexed - 26 DNA variants covering SNVs, INDELs, and SVs
- Blended against a well-characterized GM24385 WT cell line background
- VAF range between 5% to 15% based on digital PCR quantitation
- Manufactured under cGMP and ISO 13485
